An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.
Eva IniguezNathaniel S SchockerKrishanthi SubramaniamSusana PortilloAlba L MontoyaWaleed S Al-SalemCaresse L TorresFelipe RodriguezOtacilio C MoreiraAlvaro Acosta-SerranoKatja MichaelIgor Correia de AlmeidaRosa A MaldonadoPublished in: PLoS neglected tropical diseases (2017)
We propose that NGP5B is an attractive candidate for the study of potential synthetic α-Gal-neoglycoprotein-based vaccines against L. major infection.
Keyphrases